Nyrada Inc is a new US biotechnology company.
Our business is drug discovery and drug development in areas of significant community need. These are diseases and conditions affecting large numbers of individuals, where current treatments are viewed as being poor, and in some cases, non-existent.
The guiding principles driving our commercial strategies are:
The Company’s strategy is to demonstrate the therapeutic utility of its patented drug candidates towards commercialization in global markets. Applications are selected based on sound scientific rationale, significant unmet clinical need, compelling market opportunity, and the potential for favourable regulatory treatment with a clear path to approval.
Nyrada has 3 pipeline drugs under development across 2 broad clinical streams.
NYX-104. A neuro-protectant drug. A TrpC3 inhibitor intended to protect the nervous system from excitotoxicity, or the after-shock damage that follows death of brain cells. Excitotoxicity is a well-recognized, key mechanism for damage to the brain, which occurs in the hours and days following a stroke or traumatic brain injury such as concussion or accident. Currently there are no drugs approved that block excitotoxicity and offer the ability to limit the extent of damage to the brain following injury.
NYX-205. An anti-inflammatory drug. NYX-205 inhibits the enzyme, thromboxane synthase, blocking the production of thromboxane, a key component of the inflammatory process, and a putative major contributor to a number of different forms of chronic inflammation including:
NYX-330. A cholesterol-lowering drug. A small molecule inhibitor of PCSK9 for the treatment of hypercholesterolemia or elevated blood levels of LDL (low density lipoprotein) cholesterol where it presents a risk factor for cardiovascular disease. The objective is to develop an oral drug that can be used in combination with the standard statin cholesterol-lowering drugs, or for use in individuals unable to use statins for safety reasons.